It’s hard to believe 2023 is already coming to a close – it’s remarkable to think about how much we’ve accomplished here at Lindus Health. With 2024 on the horizon, it’s only fitting we reflect on our triumphs from these past twelve months that have and will continue to shape Lindus Health’s journey.

‍

Our ultimate mission here is to bring groundbreaking therapies to patients more quickly – and we accomplish this by running clinical trials radically faster than traditional CROs. We recognize this is a tall order, as there are many dynamic components at play in managing a study. I have the utmost gratitude for the Lindus Health team, as together we have proven our success in this by completing trials 3-times faster than our competitors. In the past year alone we’ve completed 22 end-to-end trials (nearly a quarter of our total to date), engaging with over 5,750 patients who have played a part in advancing healthcare. That’s an incredible win if I say so myself.

‍

I would also like to extend much appreciation to our remarkable investors who believe in Lindus Health’s mission as much as we do. Thanks to them, we were able to raise $18m USD in our Series A round of funding. At the start of 2023 we were a team of 22 and we’ve more than doubled our headcount since then, and we look forward to growing our commercial and operations teams further in 2024.

‍

In the very beginning of this year, our very own Machine Learning Engineer, Ece Kavalci, was published in Nature for her work using machine learning models to predict early termination in clinical trials in efforts to streamline the process of protocol development. As many in this industry know, it can be extremely laborious to design a protocol and study, and even after all the time and effort amendments may be necessary as the study plays out. The use of this technology effectively streamlines protocol and study development as part of our mission to accelerate clinical research and deliver life-changing therapies to patients sooner. At Lindus we’re extremely keen on using AI when we can to deliver results quickly and will continue to do so more in the next year as well.

‍

Overall, 2023 has been a huge year of growth for our business – we’ve been able to diversify our portfolio of expertise by working on some pretty unique trials in digital therapeutics. In July we announced our collaboration with Dopavision, a Berlin-based digital ophthalmology health startup, on a trial that uses VR headsets to deliver treatment for myopia (short sightedness) in children. Research has shown that myopia has become increasingly prevalent over time, so we are thrilled to be working on an extremely innovative project that has the potential to have a positive impact on children with this indication. The digital therapeutics market has demonstrated substantial promise for our prosperity, and we eagerly anticipate further expansion in this market segment throughout 2024.

‍

We’ve been fortunate to dive deeper into diagnostics this year as well with several ongoing trials, one being with Daye, a female-founded gynaecological health startup that invented the world’s first cannabidiol (CBD) tampon. Together, we’re executing a study for a diagnostic tampon that will be able to detect HPV and other STIs in those assigned female at birth. Delivering exceptional patient experience is a priority for us, and if successful, this product has the potential to do just that by offering a non-invasive and convenient way for women to access these tests.

As you can tell, Lindus Health has come a long way over the past year and we have a lot of momentum coming into 2024. Our unwavering dedication to do everything we can to accelerate clinical trials to advance healthcare is stronger now more than ever. We are incredibly grateful for the opportunity to work on all the research projects we’ve won and can’t wait to see what next year has in store for us.

‍

Thank you to everyone who has supported us along the way, and happiest of new years!